SGMO - Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR

Brian Ach/Getty Images Entertainment Intellia Therapeutics ([[NTLA]] +7.7%) has gained more than 80.0% since the company joined Gilead Sciences ([[GILD]] +1.2%) over the weekend to unveil the first first-ever clinical data to support the safety and efficacy of in-vivo CRISPR genome editing in humans. At the recently concluded CNBC Global Evolve Summit, the company’s co-founder Jennifer Doudna, who won the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing has laid out what is ahead for the technology in terms of opportunities and challenges. The interim Phase 1 data released on Saturday indicated the ability of CRISPR candidate NTLA-2001 to genetically edit liver cells in transthyretin amyloidosis ((ATTR)). According to Doudna, getting the edited molecules to the targeted organs remains a challenge. “We have the editors; we just don’t know how to get them where they need to go,” Nobel laureate explained. “This is especially an issue in clinical medicine

For further details see:

Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR